Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-719 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 ABT-719 lower dose | EXPERIMENTAL | - |
| Arm 2 ABT-719 intermediate dose | EXPERIMENTAL | - |
| Arm 3 ABT-719 higher dose | EXPERIMENTAL | - |
| Arm 4 placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-719 | DRUG | 1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose |
| Placebo | DRUG | Placebo infusion |
Inclusion Criteria: * Subject must be male or female, age greater than or equal to 18 years old. * Subjects must have stable renal function, per Investigator discretion and no known increase in serum creatinine of greater than or equal to 0.3 mg during the preceding 4 weeks. * Subjects with estimat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
ABT-719 is an investigational small molecule being studied for the prevention of acute kidney injury in patients undergoing high-risk cardiac surgery. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
The molecular target of ABT-719 has not been disclosed in available information. The drug is being evaluated for its potential to prevent acute kidney injury, but its specific mechanism of action is not publicly detailed.
ABT-719 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
ABT-719 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it is not yet approved for commercial use.
ABT-719 has one completed Phase 2 trial, NCT01777165, which evaluated multiple dosing regimens for the prevention of acute kidney injury in subjects undergoing high-risk cardiac surgery. The trial enrolled 240 participants in the United States and Denmark.
No alternative names for ABT-719 have been reported. The drug is identified solely by its code name ABT-719 in clinical trial registries and available information.